Mineral metabolism parameters throughout chronic kidney disease stages 1–5—achievement of K/DOQI target ranges
Craver Hospital, Lourdes
Marco Mayayo, M. Paz
Martín Ramos, María Luisa
MetadataShow full item record
BACKGROUND: Dialysis Outcomes and Practice Patterns Study has shown that the proportion of haemodialysis patients with adequate mineral metabolism parameters according to the Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines is very low. The adequacy of such parameters in relation to the
recommended ranges in patients with different chronic kidney disease (CKD) stages has not been reported. The objective of this study is to provide an in-depth description of mineral metabolism in the early stages of CKD in a European population, and to compare it with current recommendations for stages 3-5 (K/DOQI guidelines). METHODS: A total of 1836 patients were classified into stages 1-5 according to K/DOQI guidelines. The following clinical and biochemical data were recorded: age, gender, CKD aetiology, presence of diabetes, serum creatinine, creatinine clearance, serum phosphate, calcium, CaxP product and intact parathyroid hormone (PTH). RESULTS: A decrease in 1,25-dihydroxyvitamin D and an increase in PTH are the earliest mineral metabolism alterations in CKD, while serum calcium and phosphate are altered later in the course of CKD. The percentages of patients with serum levels within the recommended K/DOQI guidelines for stages 3, 4 and 5 were as follows: serum calcium: 90.7, 85.6 and 55; serum phosphate: 90.9, 77.1 and 70.3; iPTH 42.4, 24.6 and 46.8 and Ca x P product 99.9, 99.6 and 83.8, respectively. The percentages of patients who had all four parameters within the recommended ranges were 34.9, 18.4 and 21.6 for stages 3, 4 and 5, respectively. CONCLUSION: Mineral metabolism disturbances start early in the course of CKD. The first alterations to take place are a 1,25-dihydroxyvitamin D decrease, a 24 h urine phosphate decrease and a PTH elevation, which show significant level variation when the glomerular filtration rate falls below 60 ml/min. K/DOQI recommended levels for mineral metabolism parameters are difficult to accomplish, in particular for PTH levels.
Is part ofNephrology Dialysis Transplantation, 2007, vol. 22, núm. 4, p. 1171-1176
Showing items related by title, author, creator and subject.
Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: The NEFRONA project Junyent, Mireia; Martínez Alonso, Montserrat; Borràs, Mercè; Betriu i Bars, M. Àngels; Coll, Blai; Craver Hospital, Lourdes; Marco Mayayo, M. Paz; Sarró, Felipe; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira (Sociedad Española de Nefrologia, 2010)Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Cardiovascular risk assessment in this population is hampered by the failure of ...
Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study Junyent, Mireia; Martínez Alonso, Montserrat; Borràs, Mercè; Coll, Blai; Valdivielso Revilla, José Manuel; Vidal, Teresa; Sarró, Felipe; Roig, Jordi; Craver Hospital, Lourdes; Fernández i Giráldez, Elvira (BioMed Central, 2010)Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Cardiovascular risk assessment in this population is hampered by the failure of ...
A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients Craver Hospital, Lourdes; Dusso Rosso, Adriana; Martínez Alonso, Montserrat; Sarró, Felipe; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira (BioMed Central, 2013)Background: Vascular calcification (VC) contributes to high mortality rates in chronic kidney disease (CKD). High serum phosphate and FGF23 levels and impaired phosphaturic response to FGF23 may affect VC. Therefore, ...